This week in techniques



Licensing status

Publication and contact information

Assays & screens

In vivo shRNA screen to identify immunosuppressive tumor targets

In vivo shRNA screens could be used to identify immunosuppressive tumor targets to enhance T cell immunotherapy. In melanoma-bearing mice injected with T cells expressing an shRNA library, deep sequencing determined that shRNA targeting protein phosphatase 2 regulatory subunit Bd (Ppp2r2d) increased T cell accumulation in tumors compared with in spleens. In the mice, T cells expressing Ppp2r2d-targeting shRNA showed greater tumor infiltration, proliferation and survival, and also greater mouse survival, than T cells expressing a control shRNA. Next steps could include testing T cells that express a chimeric antigen receptor (CAR) plus PPP2R2D-targeting shRNA in animal models of cancer (see Micromanaging the microenvironment, page 9).

SciBX 7(6); doi:10.1038/scibx.2014.180
Published online Feb. 13, 2014

Patent and licensing status undisclosed

Zhou, P. et al. Nature;
published online Jan. 29, 2014;
Contact: Kai W. Wucherpfennig,
Dana-Farber Cancer Institute, Boston, Mass.